Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Colfax Corporation    CFX


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Colfax : DJO® Introduces Two New EMPOWR™ Systems Designed To Accelerate Surgical Efficiency

08/20/2020 | 07:04am EST

The EMPOWR Acetabular™ System and EMPOWR Partial Knee™ restore healthy kinematics and promote surgical efficiency with single-tray implantation

DJO, LLC (“DJO” or the “Company”), a leading global provider of medical technologies to get and keep people moving, today announced two new EMPOWR™ systems, EMPOWR Acetabular™ and EMPOWR Partial Knee™. Both systems were designed to restore healthy kinematics and optimize surgical procedure efficiencies by allowing implantation with a single tray.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005295/en/

EMPOWR Acetabular™ System (Photo: Business Wire)

EMPOWR Acetabular™ System (Photo: Business Wire)

With more than 450,000 total hip arthroplasty (THA)1 and 75,000 unicompartmental knee arthroplasty (UKA)2 procedures performed each year in the United States, the EMPOWR Acetabular and Partial Knee Systems provide surgeons with a comprehensive and efficient solution for all THA and UKA approaches and settings. Instrument efficiency makes these systems especially relevant for outpatient and ambulatory surgery center procedures where surgeons may place an even greater priority on cost minimization opportunities.

“We are building on the proven success, deep clinical research, and differentiated design technologies of the EMPOWR™ platform with the launch of these new systems,” noted Louis Vogt, VP of Sales & Marketing of DJO Surgical®. “DJO is committed to improving patient outcomes and surgeon success, and with just a single tray, these EMPOWR systems will enable surgeons to be more efficient and effective, especially in the rapidly growing outpatient setting.”

EMPOWR system efficiency is driven by premium, intelligently designed single-tray instrumentation, resulting in up to a 50% reduction in storage and sterilization costs compared to other systems on the market3. Streamlined, intuitive instrumentation was designed to improve surgical workflow by reducing turnover time and waste. “These EMPOWR advances support the acceleration of outpatient total joint procedures and the procedure migration to the ASC setting where surgeons increasingly rely on streamlined solutions,” Vogt said.

EMPOWR Acetabular System

The EMPOWR Acetabular System design leverages anthropometric data and advanced material technologies to help restore healthy kinematics and individual patient anatomy. P2™, a proprietary Titanium porous coating that aids in the apposition of bone, has shown on a legacy design the disappearance of zone 2 radiolucent lines at one year follow-up signifying osseointegration4,5. HXe+™ liners are specifically designed for ball and socket kinematics and blended with vitamin E to significantly reduce oxidation and long-term wear6.

“I’ve been using the EMPOWR Primary Knee System® on patients for years, and I am extremely pleased with the early results of the EMPOWR Acetabular System,” said Dr. Douglas Padgett, Chief of Adult Reconstruction and Joint Replacement Service at the Hospital of Special Surgery in New York City and former President of The Hip Society. “The EMPOWR Acetabular System provides predictable biologic fixation with P2 in-growth coating and acetabular screw placement. Enhanced features such as reliable liner locking feature, larger diameter heads in smaller shells, and efficient one-tray design have made this implant my acetabular system of choice,” noted Padgett.

EMPOWR Partial Knee™

The EMPOWR Partial Knee™ was developed with the same advanced material technologies and joint restoration principles as the EMPOWR™ Knee Platform, one of the industry’s most modern total knee systems, which has been clinically validated to increase patient satisfaction7. The EMPOWR Partial Knee was also designed using anthropometric data to create anatomically shaped femoral and tibial components for comprehensive bone coverage in either medial or lateral compartments while minimizing the potential for overhang and maximizing natural motion.

"EMPOWR is the knee of choice for all of my primary total knee replacements. The addition of the EMPOWR Partial Knee allows me to provide the full continuum of care from isolated unicompartmental disease to complex primary/revision knees with associated bone loss,” said Dr. Scott Sporer, Professor, Orthopaedic Surgery at Rush University Medical Center and Midwest Orthopaedics at Rush in Chicago, IL. “The outstanding clinical outcomes and predictable kinematics within the EMPOWR line of implants has allowed countless patients in my practice to return to their active lifestyles. In this ever changing medical climate, DJO has delivered a system that provides one tray of intuitive instrumentation to aid in efficiency and cost savings,” noted Sporer.

For more information about DJO’s industry-leading EMPOWR brand, visit djoglobal.com/empowr.


  1. https://orthoinfo.aaos.org/en/treatment/total-hip-replacement/
  2. SmartTrak – US Knee Replacement Procedures, 2019
  3. Based on calculation of no. of trays compared to DePuy Pinnacle and Zimmer Biomet G7. https://www.ajog.org/article/S0002-9378(16)30358-1/pdf for cost of sterilization
    Based on calculation of no. of trays compared to Oxford Uni Knee.
  4. P2™ Testing Summary 0020327-001 Rev A 10/14. Laboratory testing does not necessarily indicate clinical performance.
  5. Zielinski M, Deckard E, Meneghini M. The fate of zone 2 radiolucencies in contemporary highly-porous acetabular components: not all designs perform equally. Poster session presented at: 2017 AAHKS Annual Meeting; Nov 2-5: Dallas, TX.
  6. e+™ testing data on file. Bench test results not necessarily indicative of clinical performance.
  7. “Replicating Native Knee Dual-Pivot Kinematics Improves Outcomes After Total Knee Arthroplasty. R. Michael Meneghini MD – ICJR South Presentation June 2018.

Dr. Douglas Padgett and Dr. Scott Sporer are paid consultants for DJO®.

About DJO®

DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.

© Business Wire 2020
01/15COLFAX : UBS Adjusts Price Target on Colfax to $45 From $40, Reiterates Buy Rati..
01/07INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Colfax
2020INSIDER TRENDS : 90-Day Insider Buying Trend at Colfax Interrupted with Sale of ..
2020COLFAX : Deutsche Bank Adjusts Price Target for Colfax to $39 From $36, Maintain..
2020COLFAX : Morgan Stanley Adjusts Colfax' Price Target to $39 from $30, Keeps Equa..
2020INSIDER TRENDS : Insider Purchase Continues Colfax Positive Trend
2020COLFAX : DJO, a Subsidiary of Colfax, Acquires LiteCure Laser Therapy for Undisc..
2020COLFAX : DJO® Acquires LiteCure Laser Therapy
2020Barclays Adjusts Colfax's Price Target to $35 From $31, Keeps Equal-Weight Ra..
2020KeyBanc Adjusts Colfax's Price Target to $44 From $36, Keeps at Overweight
More news
Financials (USD)
Sales 2020 3 070 M - -
Net income 2020 48,6 M - -
Net Debt 2020 2 099 M - -
P/E ratio 2020 102x
Yield 2020 -
Capitalization 4 588 M 4 588 M -
EV / Sales 2020 2,18x
EV / Sales 2021 1,91x
Nbr of Employees 15 000
Free-Float 84,9%
Duration : Period :
Colfax Corporation Technical Analysis Chart | CFX | US1940141062 | MarketScreener
Technical analysis trends COLFAX CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 18
Average target price 43,50 $
Last Close Price 38,73 $
Spread / Highest target 47,2%
Spread / Average Target 12,3%
Spread / Lowest Target -9,63%
EPS Revisions
Managers and Directors
Matthew L. Trerotola President, Chief Executive Officer & Director
Mitchell P. Rales Non-Executive Chairman
Christopher Michael Hix CFO, Treasurer & Senior Vice President
Patrick William Allender Independent Director
Thomas Sinnickson Gayner Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ATLAS COPCO AB8.31%63 496
SANDVIK AB8.49%32 717